Program Overview — Status: Operational
The 340B drug discount program requires pharmaceutical manufacturers to sell qualifying hospitals outpatient drugs at discounts of 20 to 50 percent. The justification for these discounts, stated in the program's legislative history and cited routinely in regulatory filings, is that the savings benefit low-income and uninsured patients.
The Congressional Research Service, which is the nonpartisan federal body responsible for interpreting what statutes actually say, states the following: "Providers may pass the drug discounts on to patients, but the statute does not require them to do so."
The program requires the discount. It does not require the charity. The charity was the reason for the program.
The Bureau of Charitable Transactions, Discount Disbursement Division, presents this arrangement as a standard administrative feature of the 340B program and is filing this dispatch as a courtesy notice to any parties who assumed the two things were connected.
Section I — The Compliance Inventory
The Bureau has prepared the following inventory of obligations under the 340B program. Each item is drawn from program statute, Congressional Research Service documentation, and GAO oversight reports.
1. Required: Disproportionate Share Hospital status or qualifying safety-net designation A covered entity must demonstrate that it serves a qualifying patient population, as defined by Medicaid disproportionate share metrics or analogous safety-net criteria. The patient population is the qualification. It is not the beneficiary requirement. These are different things.
2. Required: Drug purchasing through HRSA-administered Prime Vendor Program Covered entities must purchase 340B-discounted drugs through the program's authorized channels. In 2024, 340B covered entities purchased $81.4 billion in drugs through these channels — a 23% increase over 2023. The program is, in purchasing terms, the second-largest federal pharmaceutical program after Medicare Part D.
3. Required: Maintaining auditable records of 340B drug usage Covered entities must keep records demonstrating that 340B drugs are dispensed to qualifying patients and that drugs are not simultaneously billed to Medicaid (duplicate discounting). HRSA audits are the mechanism for verifying this. HRSA currently audits approximately 0.33% of covered entities per year, which, at current capacity, would complete a single review cycle of all participants in approximately 2326.
4. Not required: Passing savings to low-income patients The statute does not require it. The Congressional Research Service confirms it is not required. No federal mechanism exists to verify that it occurs.
5. Not required: Spending 340B revenue on charity care The statute does not require it. In 47 states and the District of Columbia, more than half of 340B Disproportionate Share Hospitals bring in more 340B revenue than they spend on charity care, according to a Third Way analysis of public hospital financial records.
6. Not required: Providing more charity care than non-participating hospitals The statute does not require it. Multiple independent analyses — including a Third Way memo, a Marquette University study of Michigan hospitals, and a review of federal cost report data — find that 340B-participating hospitals provide less charity care than non-participating hospitals. The Marquette analysis found that Michigan 340B hospitals delivered 34% less charity care than non-340B hospitals while investing 113% more into financial markets. The program's eligibility criterion is serving low-income patients. The program's outcome, as documented across multiple datasets, is serving fewer low-income patients than hospitals that do not participate.
BUREAU NOTE: The Bureau's records show that the 340B program was established in 1992 as Section 340B of the Public Health Service Act. The Bureau's records also show that the 1992 statute "did not specify or obligate the entities as to how program savings should be used or shared," as confirmed in a peer-reviewed editorial in Health Affairs. The Bureau notes that thirty-four years is an unusual duration for a pending administrative clarification, but that the program's 23% annual growth rate suggests the clarification is not urgently required by anyone currently benefiting from the arrangement.
Section II — Scale Note
The Bureau wishes to note, for reference purposes, the approximate scale of the program.
The gross-to-net spread — the difference between list prices and 340B discounted prices — reached $66.4 billion in 2024. This is an approximation of the total value retained by covered entities, though actual margins vary based on insurance reimbursement rates. The figure represents approximately 19% of all brand-name drug gross-to-net reductions in the United States.
Cleveland Clinic, according to a Third Way analysis of public records, generated more than $900 million in 340B program profits between April 2020 and June 2023. NYU Langone, one of the United States' largest and most prominent hospital systems, spent less than 0.34% of its $7.2 billion annual revenue on charity care while participating in the program.
The Bureau presents these figures without editorial characterization. The Bureau notes that characterization is available upon request, but that the figures are carrying their own weight.
Section III — The Recent Filing
On March 12, 2026, Governor Bob Ferguson of Washington state signed Senate Bill 5981 into law. The law requires pharmaceutical manufacturers to allow contract pharmacy access to 340B drugs and prohibits manufacturers from conditioning drug delivery on data submission by hospitals. It does not require hospitals to document their charity care spending. It does not require hospitals to pass savings to patients. It does not address the charity care gap in any direct way.
It requires, specifically, that the drugs go where they are supposed to go.
On March 30, 2026, Novartis and AbbVie filed a federal lawsuit in the Western District of Washington to block the law from taking effect. The effective date is June 10, 2026. The penalty for violations is $5,000 per day.
AbbVie's complaint argues that the transparency requirement will cost it "tens of millions of dollars in unrecoverable discounts" and that the law has "cascading constitutional infirmities." The complaint also argues that requiring manufacturers to allow pharmacy access to a discount program constitutes an unconstitutional taking under the Fifth Amendment — that is, that documentation of how a charity-care-justified subsidy moves through the supply chain is a seizure of private property.
The Bureau notes that the entities suing to prevent documentation of the charity program are the entities providing the discounts — not the entities providing the charity. The entities providing less charity care than non-participating hospitals have not filed suit. They have no reason to. The transparency law does not cover them.
BUREAU NOTE: A similar transparency law was upheld by the Fifth Circuit Court of Appeals in February 2026. The Bureau does not offer legal predictions. The Bureau notes that the legal question being litigated is whether the government may require participants in a federal charity program to allow the charity to reach its intended recipients — and that this question, in the Bureau's filing, represents a fairly advanced stage of institutional drift from the program's founding premise.
Section IV — Oversight Architecture
For completeness, the Bureau documents the federal oversight structure for the 340B program.
The Health Resources and Services Administration is the program's oversight authority. In October 2025, the Government Accountability Office reported that HRSA's audit coverage of covered entities runs at approximately 0.33% per year. The GAO also reported that HRSA has no mechanisms to verify that 340B savings are used to support vulnerable populations — the program's stated beneficiaries. Multiple GAO recommendations from prior years remain unimplemented.
The program currently has no federal pass-through requirement, no charity care floor, and an annual audit rate that, at current capacity, would not complete a single review cycle within any living participant's expected lifespan.
The Bureau finds this oversight architecture adequate for the program as written.
Section V — Classification
The Bureau of Charitable Transactions, Discount Disbursement Division, classifies the 340B program's charity care function as follows:
Status: Aspirational
Statutory basis: Legislative history, not enforceable obligation
Current performance against stated purpose: Below national average, as documented by multiple independent analyses
Federal enforcement mechanism: Not operationalized
Pending clarification: Since 1992
The program requires the discount. It does not require the charity. The charity was the reason for the program.
Whether that sentence requires a follow-up action is a question the Bureau leaves to the relevant oversight authority — which, as noted above, completes approximately 0.33% of its review workload per year and has not yet scheduled the conversation.
Bureau of Charitable Transactions, Discount Disbursement Division — a sub-bureau of the Bureau of Public Agreement. Classification pending. Clarification not urgently expected.